Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
23:49
The Mayor of Sector 1, George Cristian Tuță, announces that he has notified the authorities regarding the damage caused during the farmers' protest
23:24
The US has spent nearly 38 billion dollars in six months of war with Iran
23:17
Venezuela’s former Minister of Industry admits his guilt in the US and could cooperate in investigations targeting Nicolás Maduro
23:02
The Capital Police detained a 34-year-old man found with a knife at the protest in Victory Square
22:59
The Trump administration intends to sell Israel a $2.8 billion package of munitions
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
